Resonate Blends, Inc. (KOAN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Resonate Blends, Inc. (KOAN) trades at $0.00 with AI Score 62/100 (Grade B+). APOLLO BioWellness Inc. Market cap: $136,674, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for KOAN: KOAN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KOAN against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
KOAN: 2/4 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Resonate Blends, Inc. (KOAN) Healthcare & Pipeline Overview
APOLLO BioWellness Inc. operates within the healthcare sector, specializing in regenerative medicine through licensed patent-pending natural stem cell mobilizing agents and an all-natural diet aid. The company also researches natural bioactive formulations for human performance, positioning itself in the niche market of non-pharmaceutical wellness solutions.
What Is the Investment Thesis for KOAN?
APOLLO BioWellness Inc. (KOAN) presents an investment profile centered on its participation in the regenerative medicine and natural health product markets. The company's strategy focuses on licensed patent-pending natural stem cell mobilizing agents and an all-natural diet aid, tapping into growing consumer demand for non-pharmaceutical wellness solutions. With a gross margin of 79.7%, the company demonstrates strong product-level profitability, indicating efficient cost management relative to revenue from its offerings. However, a significant profit margin of -151.0% reflects substantial operational expenses relative to its revenue base, typical for a small company engaged in R&D and market development. The high Beta of 3.65 suggests considerable price volatility, which could appeal to investors seeking higher risk-reward profiles. Future growth catalysts include successful market penetration of its existing licensed products, positive outcomes from ongoing research into secretogues and other natural bioactive formulations, and potential expansion of its product portfolio. The company's ability to scale its marketing efforts and secure additional intellectual property will be crucial value drivers, alongside managing its operational burn rate to improve profitability.
Based on FMP financials and quantitative analysis
KOAN Key Highlights
- Gross Margin of 79.7% indicates strong product-level profitability for APOLLO BioWellness Inc.'s offerings.
- Profit Margin of -151.0% reflects significant operational expenses relative to revenue, typical for a development-stage company.
- Market Capitalization of 137K signifies a micro-cap company, often associated with higher risk and potential for volatility.
- Beta of 3.65 suggests APOLLO BioWellness Inc.'s stock price is highly volatile compared to the broader market.
- The company operates with a lean team of 6 employees, indicating a focused operational structure for its specialized product development and marketing.
Who Are KOAN's Competitors?
KOAN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| CRON Cronos Group Inc. | $2.76 | -3.50% | $1.03B | 62 |
| TXMD TherapeuticsMD, Inc. | $1.98 | -6.40% | $22.86M | 62 |
| VREOF Vireo Growth Inc. | $9.75 | -2.01% | $372.96M | 62 |
| LNTH Lantheus Holdings, Inc. | $106.91 | -2.71% | $6.96B | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KOAN's Key Strengths?
- Licensed patent-pending natural stem cell mobilizing agents provide a unique product offering.
- Focus on all-natural, drug-free formulations aligns with growing consumer preferences.
- Strong gross margin of 79.7% indicates efficient cost management at the product level.
- Engagement in research and development for future natural bioactive formulations.
What Are KOAN's Weaknesses?
- Significant negative profit margin of -151.0% indicates substantial operational losses.
- Very small company size with only 6 employees, limiting operational scale and resources.
- Unknown disclosure status on the OTC market creates transparency challenges for investors.
- High stock price volatility (Beta 3.65) may deter risk-averse investors.
What Could Drive KOAN Stock Higher?
- Successful commercialization and market penetration of its licensed natural stem cell mobilizing agents, driving increased sales volume.
- Positive results from ongoing research and development into secretogues and other natural bioactive formulations, leading to new product pipeline announcements.
- Expansion of marketing and distribution channels for the all-natural diet aid, potentially through new partnerships or direct-to-consumer strategies.
- Any improvements in disclosure status or financial reporting on the OTC Markets, which could enhance investor confidence and transparency.
- Securing additional intellectual property or exclusive licenses for new natural health products, strengthening its competitive position.
What Are the Key Risks for KOAN?
- Financial-distress signal — its Altman Z-Score of -20.85 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant negative profit margin of -151.0% indicates substantial operational losses, raising concerns about long-term financial sustainability without significant revenue growth or cost reduction.
- High stock price volatility (Beta 3.65) and low liquidity on the 'OTC Other' tier could lead to unpredictable share price movements and difficulty for investors to exit positions.
- Dependence on the successful commercialization of licensed patent-pending products, which face market acceptance challenges and competition from established players.
- Regulatory hurdles and evolving scientific consensus regarding the efficacy and safety of natural stem cell mobilizing agents and secretogues could impact product viability.
- Limited public disclosure ('Unknown' status) and a small operating team of 6 employees may hinder investor confidence and the company's ability to scale operations effectively.
What Are the Growth Opportunities for KOAN?
- Growth opportunity 1: Expansion in the Regenerative Medicine Market. The global regenerative medicine market is projected to grow significantly, driven by advancements in cell therapies and increasing prevalence of chronic diseases. APOLLO BioWellness Inc.'s licensed patent-pending natural stem cell mobilizing agents position it to capitalize on this trend. By increasing awareness and distribution channels for these products, the company can tap into a patient population seeking natural methods to enhance their body's regenerative capabilities. Successful clinical validation or widespread adoption could significantly expand its market reach over the next 3-5 years, particularly as consumer acceptance of natural health solutions continues to rise.
- Growth opportunity 2: Commercialization of Natural Diet Aids. The market for weight management products and diet aids remains robust, fueled by rising obesity rates and health consciousness. APOLLO BioWellness Inc.'s dual-acting, all-natural diet aid, designed to control hunger through normal body signals, offers a differentiated product in a crowded market. Focusing on its natural formulation and mechanism of action can attract consumers wary of synthetic ingredients or harsh side effects. Strategic marketing and partnerships with health and wellness retailers could drive significant sales growth for this product over the next 2-4 years, establishing a steady revenue stream.
- Growth opportunity 3: Development of Secretogues for Growth Hormone Enhancement. Research and development into secretogues to enhance natural growth hormone production represents a substantial long-term growth opportunity. The anti-aging and performance enhancement markets are large and continuously seeking innovative, natural solutions. If APOLLO BioWellness Inc. successfully develops and commercializes such formulations, it could tap into a high-value market segment. This opportunity, while requiring significant R&D investment and regulatory navigation, could yield substantial returns within a 5-10 year timeline, establishing the company as a leader in natural human performance enhancement.
- Growth opportunity 4: Diversification into Natural Bioactive Formulations for Human Performance. Beyond secretogues, the company's research into similar natural bioactive formulations to enhance human performance without drugs opens up a broad spectrum of potential products. This could include natural cognitive enhancers, energy boosters, or recovery aids. The global dietary supplements market, including performance-enhancing supplements, is a multi-billion dollar industry. Leveraging its expertise in natural mechanisms, APOLLO BioWellness could develop a pipeline of products targeting various aspects of human performance, creating multiple revenue streams over the next 4-7 years and reducing reliance on a single product category.
- Growth opportunity 5: Strategic Licensing and Partnership Opportunities. Given its focus on licensed patent-pending products and ongoing R&D, APOLLO BioWellness Inc. has the potential to engage in strategic licensing agreements or partnerships. Collaborating with larger healthcare or wellness companies could provide access to broader distribution networks, increased marketing resources, and accelerated product development. Such partnerships could significantly de-risk its commercialization efforts and provide capital for further research. This strategy could unlock substantial value within a 2-5 year timeframe, allowing the company to scale its operations and market presence more rapidly than through organic growth alone.
What Opportunities Does KOAN Have?
- Growing global demand for regenerative medicine and natural health products.
- Expansion into the large and evolving natural diet aid and weight management markets.
- Potential for new product development in secretogues and human performance enhancement.
- Strategic partnerships or licensing agreements to expand distribution and market reach.
What Threats Does KOAN Face?
- Intense competition from established pharmaceutical companies and numerous natural supplement providers.
- Regulatory hurdles and evolving standards for natural health products and claims.
- Reliance on successful commercialization of licensed products and R&D outcomes.
- Funding challenges inherent to small, development-stage companies with negative profitability.
- Market acceptance and perception of natural alternatives versus conventional treatments.
What Are KOAN's Competitive Advantages?
- Possession of licensed patent-pending natural stem cell mobilizing agents, offering a degree of intellectual property protection.
- Focus on all-natural, drug-free formulations, appealing to a specific and growing consumer segment.
- Specialization in leveraging known body mechanisms for health enhancement, differentiating from synthetic drug approaches.
- Niche market positioning in regenerative medicine and natural performance enhancement.
- Proprietary research and development efforts in secretogues and other bioactive compounds.
What Does KOAN Do?
APOLLO BioWellness Inc., trading under the ticker KOAN, is a healthcare company based in North Bergen, New Jersey, dedicated to the discovery, development, and marketing of innovative products within the field of regenerative medicine. The company's core focus revolves around enhancing human well-being through natural mechanisms. A significant part of its current operations involves the marketing of licensed patent-pending natural stem cell mobilizing agents. These agents are designed to support an individual's intrinsic ability to mobilize their own adult stem cells from bone marrow, a process critical for the body's natural repair and regeneration. This approach aligns with a growing consumer interest in natural health solutions and preventative care. Beyond regenerative medicine, APOLLO BioWellness Inc. holds a license to market a dual-acting, all-natural diet aid. This product aims to assist in hunger control by leveraging normal body signals directed to the brain and stomach, offering a non-pharmacological option for weight management. The company's strategic vision extends into active research and development, exploring additional areas of natural bio-enhancement. This includes investigations into secretogues, which are compounds intended to enhance a person's endogenous growth hormone production, and similar natural bioactive formulations. These research initiatives are geared towards improving overall human performance by utilizing known physiological mechanisms, explicitly avoiding the use of synthetic drugs. With a small team of 6 employees, APOLLO BioWellness Inc. maintains a focused approach on developing and commercializing natural health products, aiming to carve out a distinct position in the competitive healthcare and wellness landscape.
What Products and Services Does KOAN Offer?
- Discovers and develops products in the field of regenerative medicine.
- Markets licensed patent-pending natural stem cell mobilizing agents.
- Focuses on enhancing individuals' ability to mobilize their own adult stem cells from bone marrow.
- Holds a license to market a dual-acting, all-natural diet aid for hunger control.
- Conducts research and development on secretogues to enhance natural growth hormone production.
- Explores natural bioactive formulations to enhance human performance without using drugs.
- Aims to utilize known body mechanisms for health and wellness solutions.
How Does KOAN Make Money?
- Generates revenue through the marketing and sale of licensed natural stem cell mobilizing agents.
- Derives income from the sale of its licensed dual-acting, all-natural diet aid.
- Invests in research and development for future natural health and performance enhancement products.
- Potentially seeks additional licensing opportunities for its patent-pending formulations.
- Focuses on a product-centric model within the natural health and wellness market.
What Industry Does KOAN Operate In?
APOLLO BioWellness Inc. operates within the Drug Manufacturers - Specialty & Generic industry, specifically targeting the burgeoning natural health and regenerative medicine segments. The broader healthcare sector is experiencing significant trends, including an aging global population, increased focus on preventative health, and a growing consumer preference for natural and holistic wellness solutions. The regenerative medicine market, while still evolving, is projected for substantial growth, driven by advancements in stem cell research and therapies. APOLLO BioWellness's focus on natural stem cell mobilizing agents and secretogues positions it in a niche within this market, distinct from traditional pharmaceutical drug development. The competitive landscape includes established pharmaceutical companies, smaller biotech firms, and a multitude of natural supplement providers. APOLLO BioWellness differentiates itself through its emphasis on licensed patent-pending natural formulations that leverage the body's inherent mechanisms, aiming to capture market share from consumers seeking alternatives to conventional drug-based treatments.
Who Are KOAN's Key Customers?
- Individuals seeking natural solutions for regenerative health and anti-aging.
- Consumers interested in natural methods for weight management and hunger control.
- Health-conscious individuals looking for drug-free ways to enhance human performance.
- Those exploring alternative and complementary therapies for wellness.
- Customers prioritizing natural ingredients and mechanisms in their health products.
How Resonate Blends, Inc. Is Valued
Resonate Blends, Inc. carries a market capitalization of 137K, placing it in the micro-cap category. Relative to its peer group, KOAN's quantitative score of 62/100 is roughly in line with the peer average of 67/100.
Company Profile
Resonate Blends, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in North Bergen, US. The company is led by CEO James W. Zimbler. KOAN has traded publicly since 1993.
ROE 47%Key Financial Metrics
Return on equity for Resonate Blends, Inc. stands at 47.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -89.2%, showing how much profit it generates from its asset base. A current ratio of 0.21 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 2/9Financial Health
Resonate Blends, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -20.85 places it in the distress zone, a signal of elevated financial risk.
Net sellingInsider Activity
The most recent 12 insider filings for Resonate Blends, Inc. break down as 10 sales and 2 purchases. On net that is roughly 1.8M shares disposed (about $338K), a signal worth weighing alongside the fundamentals.
KOAN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Licensed patent-pending natural stem cell mobilizing agents provide a unique product offering.
- Focus on all-natural, drug-free formulations aligns with growing consumer preferences.
- Strong gross margin of 79.7% indicates efficient cost management at the product level.
- Engagement in research and development for future natural bioactive formulations.
Bear Case
- Significant negative profit margin of -151.0% indicates substantial operational losses.
- Very small company size with only 6 employees, limiting operational scale and resources.
- Unknown disclosure status on the OTC market creates transparency challenges for investors.
- High stock price volatility (Beta 3.65) may deter risk-averse investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
KOAN Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
KOAN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KOAN.
Price Targets
Wall Street price target analysis for KOAN.
KOAN MoonshotScore
What does this score mean?
The MoonshotScore rates KOAN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: James W. Zimbler
Unknown
James W. Zimbler serves in a leadership capacity at APOLLO BioWellness Inc., managing a team of 6 employees. Specific details regarding his educational background, prior executive roles, or comprehensive career history are not publicly available within the provided source data. His role involves overseeing the strategic direction and operational execution for the company's initiatives in regenerative medicine and natural health product development.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Mr. Zimbler's leadership are not detailed in the provided information. His involvement is noted in managing the company's small team and guiding its focus on licensed natural stem cell mobilizing agents, diet aids, and ongoing research into human performance formulations.
KOAN OTC Market Information
APOLLO BioWellness Inc. trades on the 'OTC Other' tier of the OTC Markets. This tier is typically for companies that do not meet the disclosure or financial standards of higher tiers like OTCQX or OTCQB, or those that choose not to provide information to OTC Markets Group. Companies in this tier may not be current in their reporting with the SEC or other regulators, or they may be in financial distress. Trading on 'OTC Other' often implies a higher level of risk and less transparency compared to companies listed on major exchanges like NYSE or NASDAQ, which have stringent listing requirements for financial reporting, corporate governance, and market capitalization. It is the lowest tier on the OTC Markets.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Transparency: 'Unknown' disclosure status means investors have limited access to reliable and current financial information, making informed decisions difficult.
- Low Liquidity: Trading on the 'OTC Other' tier often results in very low trading volume, wide bid-ask spreads, and difficulty in buying or selling shares.
- Regulatory Scrutiny: Companies in the 'OTC Other' tier may face increased scrutiny from regulators due to lack of transparency, potentially leading to trading halts or delistings.
- Price Volatility: The stock's high Beta of 3.65, combined with low liquidity and limited information, can lead to extreme price fluctuations.
- Fraud Risk: The lack of robust reporting requirements on this tier can expose investors to a higher risk of fraudulent activities or misleading information.
- Verify the company's current financial statements and audit reports, if any are available through alternative channels.
- Research any available regulatory filings or public announcements, even if not directly from OTC Markets.
- Investigate the legitimacy of the company's licensed patent-pending products and their market viability.
- Assess the background and track record of management beyond what is publicly stated.
- Understand the company's capital structure, outstanding shares, and potential dilution risks.
- Evaluate the competitive landscape and market acceptance for its specific natural health products.
- Consider the long-term viability of the business model given its current profitability and market position.
- The company's stated focus on specific licensed patent-pending products in regenerative medicine and diet aids.
- Identified physical headquarters in North Bergen, New Jersey, providing a tangible base of operations.
- Engagement in ongoing research and development activities, indicating a commitment to product pipeline.
- A named CEO, James W. Zimbler, even with limited public background information.
- The company's existence and trading on an OTC market, however low-tier, suggests some level of formal registration.
Resonate Blends, Inc. Healthcare Stock: Key Questions Answered
What does Resonate Blends, Inc. do?
APOLLO BioWellness Inc. (KOAN) is a healthcare company primarily engaged in the discovery, development, and marketing of products within the regenerative medicine sector. Its core offerings include licensed patent-pending natural stem cell mobilizing agents, designed to enhance the body's ability to mobilize adult stem cells from bone marrow. Additionally, the company markets a dual-acting, all-natural diet aid focused on hunger control. APOLLO BioWellness also invests in research and development, exploring areas such as secretogues for natural growth hormone production and other natural bioactive formulations aimed at enhancing human performance without the use of pharmaceutical drugs, positioning itself in the natural health and wellness market.
What are the main risks for KOAN?
The primary risks for APOLLO BioWellness Inc. include its significant negative profit margin of -151.0%, indicating substantial operational losses that could challenge long-term sustainability. The company's stock exhibits high volatility (Beta 3.65) and trades on the 'OTC Other' tier with an 'Unknown' disclosure status, leading to low liquidity and transparency issues for investors. Furthermore, the business relies heavily on the successful commercialization and market acceptance of its licensed natural products, which face intense competition and potential regulatory scrutiny. The small operational team of 6 employees also presents a risk regarding the company's capacity for rapid scaling and extensive market penetration.
How does Resonate Blends, Inc. position itself within the regenerative medicine market?
APOLLO BioWellness Inc. positions itself within the regenerative medicine market by focusing on natural, non-pharmaceutical approaches. Specifically, the company markets licensed patent-pending natural stem cell mobilizing agents that aim to enhance an individual's intrinsic ability to mobilize their own adult stem cells from bone marrow. This strategy differentiates it from traditional pharmaceutical companies that often pursue synthetic drug development or more invasive cell therapies. By emphasizing natural mechanisms and avoiding drugs, APOLLO BioWellness targets a segment of the market that prefers holistic and less interventional health solutions, aligning with broader trends in natural wellness and preventative care within the evolving regenerative medicine landscape.
What are the key factors to evaluate for KOAN?
Resonate Blends, Inc. (KOAN) holds an AI score of 62/100 (moderate). Not financial advice.
How frequently does KOAN data refresh on this page?
KOAN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven KOAN's recent stock price performance?
Resonate Blends, Inc. (KOAN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Licensed patent-pending natural stem cell mobilizing agents provide a unique product offering. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KOAN overvalued or undervalued right now?
Valuing Resonate Blends, Inc. (KOAN) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying KOAN?
Before investing in Resonate Blends, Inc. (KOAN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited specific details available for CEO background and track record, resulting in 'Unknown' for those fields.
- No FMP PEER TICKERS were provided in the source data, leading to an empty 'competitors' array.
- Specific market sizes and timelines for growth opportunities were inferred based on industry context rather than explicit source data.
- The 'Unknown' disclosure status for OTC trading limits the depth of financial analysis beyond provided metrics.